Procter & Gamble Health Ltd (BSE: 500126) is a Mumbai, Maharashtra-based company in the Medicinal Chemicals and Botanical Products industry. With a market capitalisation of ₹8,354 Cr, it ranks #623 by market cap among the 6,189 Indian listed companies on FinBizNet, and #20 of 86 in Medicinal Chemicals and Botanical Products. At ₹5,032.75 (as of 26 Oct 2026), the share price is 27.8% below its 52-week high of ₹6,975.00 and 6.9% above its 52-week low of ₹4,707.00. The share price is down 18.8% over one year and down 25.3% over three months.
| Current Price | ₹5,032.75 |
|---|---|
| Market Cap | ₹8,354 Cr |
| BSE Code | 500126 |
| Sector | Health Care > Pharmaceuticals, Biotechnology and Life Sciences > Pharmaceuticals |
| Sub-Industry | Biotechnology and Life Sciences > Medicinal Chemicals and Botanical Products |
| P/E Ratio | 25.6 |
| Return on Equity | 61.59% |
| Return on Assets | 33.24% |
| 52-Week Range | ₹4,707.00 – ₹6,975.00 |
| 1-Year Price Change | -18.8% |
| 3-Month Price Change | -25.3% |
| Beta (1Y) | 0.19 |
| Dividend Yield | 1.79% |
| Headquarters | Mumbai, Maharashtra |
| Website | www.pghealthindia.com |
| Revenue | ₹364 Cr |
|---|---|
| Net Profit | ₹96 Cr |
| Net Margin | 26.4% |
| EPS (Basic) | ₹57.92 |
| Basis | standalone |
Figures in ₹ crore, parsed from the company's exchange filing (XBRL).
Procter & Gamble Health Limited manufactures and markets pharmaceuticals and chemical products in India and internationally. The company offers over-the-counter products, vitamins, minerals, and supplements. It offers its products under the Polybion, Cosome, Evion, Neurobion, Nasivion, Livogen, and Seven Seas brands. The company was formerly known as Merck Limited and changed its name to Procter & Gamble Health Limited in May 2019. Procter & Gamble Health Limited was incorporated in 1967 and is headquartered in Mumbai, India. Procter & Gamble Health Limited is a subsidiary of Procter & Gamble Overseas India B.V.
1. Segment Adjustment-This segment engages in the pharmaceuticals business. 2. Pharmaceuticals-0 3. Chemicals-This segment offers bulk drugs and pigments. 4. Corporate-0
1. Pharmaceuticals-100%
| Company | Market Cap | P/E | ROE | Latest Qtr Revenue | 1Y Change |
|---|---|---|---|---|---|
| Sun Pharmaceutical Industries Limited | ₹4,19,404 Cr | 36.6 | 14.72% | ₹15,300 Cr | +5.4% |
| Zydus Lifesciences Ltd | ₹1,12,658 Cr | 22.5 | 18.32% | ₹8,017 Cr | +14.7% |
| Cipla Limited | ₹1,08,090 Cr | 27.9 | 11.74% | ₹7,119 Cr | -14.7% |
| Laurus Labs Ltd | ₹1,06,442 Cr | 119.8 | 17.74% | ₹2,026 Cr | +125.7% |
| Dr.Reddys Lab | ₹1,02,010 Cr | 23.8 | 11.52% | ₹8,698 Cr | -0.9% |
| Mankind Pharma | ₹91,379 Cr | 47.8 | 12.45% | ₹4,031 Cr | -9.9% |
| Aurobindo Pharma Ltd. | ₹90,432 Cr | 26 | 9.93% | ₹9,150 Cr | +41.7% |
| Lupin Ltd | ₹88,018 Cr | 16.5 | 26.91% | ₹8,277 Cr | -1.1% |
| Procter & Gamble Health Ltd | ₹8,354 Cr | 25.6 | 61.59% | ₹364 Cr | -18.8% |
Listed by market capitalisation. Ratios are shown for context only.
Procter & Gamble Health Ltd is trading at ₹5,032.75, with a market capitalisation of ₹8,354 Cr.
Procter & Gamble Health Ltd operates in the Health Care > Pharmaceuticals, Biotechnology and Life Sciences > Pharmaceuticals space (Biotechnology and Life Sciences > Medicinal Chemicals and Botanical Products).
Procter & Gamble Health Ltd has a P/E of 25.6 and a return on equity of 61.59%.
Procter & Gamble Health Ltd is listed on the BSE under the scrip code 500126.
Procter & Gamble Health Ltd's share price is down 18.8% over one year and down 25.3% over three months. Its 52-week range is ₹4,707.00 to ₹6,975.00.
In Q1 FY27, Procter & Gamble Health Ltd reported revenue of ₹364 Cr and net profit of ₹96 Cr, with basic EPS of ₹57.92 (standalone, parsed from the company's exchange filing).
Data as of 26 Oct 2026. Descriptive market data only — not investment advice.